In a patient with progressive myoclonus‑ataxia who now has grade 1 spasticity and generalized hyperreflexia (corticospinal tract involvement), what are the likely differential diagnoses and recommended investigations and management?

Progressive Myoclonus-Ataxia with Pyramidal Tract Involvement: Diagnostic Approach

In a patient with progressive myoclonus-ataxia who develops spasticity and hyperreflexia, you are dealing with a spastic ataxia syndrome that significantly narrows the differential diagnosis and requires systematic genetic testing prioritizing specific gene panels based on age of onset and inheritance pattern.

Key Differential Diagnoses

The combination of myoclonus, ataxia, and pyramidal tract signs (spasticity/hyperreflexia) creates a distinct clinical entity within the broader spectrum of progressive myoclonus-ataxia syndromes. This presentation suggests:

Most Likely Genetic Causes:

For childhood/early-onset presentations 1, 2:

• GOSR2 (progressive myoclonus epilepsy with ataxia)
• SEMA6B
• ATM (ataxia-telangiectasia variant)
• KCNC3
• SPTBN2
• NUS1

For spastic ataxia phenotypes specifically 3:

• ARSACS (autosomal recessive spastic ataxia of Charlevoix-Saguenay) - most common at 17.4%
• SYNE1 (6.5%)
• ANO10, KIF1C, PGN (4.3% each)
• ZFYVE26 (SPG15)

Important consideration: The presence of pyramidal tract involvement places your patient in the "spastic ataxia" subgroup, which is predominantly autosomal recessive (unlike typical progressive myoclonus-ataxia) and carries a more severe disease burden 3.

Critical Clinical Features to Establish

Temporal Sequence Matters:

In typical progressive myoclonus-ataxia, ataxia starts first (median age 2 years), followed by myoclonus (4 years), then infrequent epilepsy (9.3 years) 4. However, your patient's pyramidal signs suggest deviation from this classic pattern.

Distinguish the Phenotype:

• Progressive Myoclonus Ataxia (PMA): Myoclonus + ataxia with infrequent, treatment-responsive seizures
• Progressive Myoclonus Epilepsy (PME): Prominent, refractory epilepsy dominates
• Spastic Ataxia: Overt spasticity (grade ≥2) with ataxia 3

Your patient appears to have a PMA-spastic ataxia overlap syndrome, which has specific genetic associations 5.

Essential Clinical Details to Document:

Neurological examination:

• Quantify spasticity grade (Modified Ashworth Scale)
• Assess for negative myoclonus (sudden muscle silence causing falls) - present in 43% of PMA patients and associated with worse motor function 5
• Document fall frequency (100% in PMA with negative myoclonus vs 37.5% without) 5
• Evaluate for cognitive impairment (62% in PMA), autism spectrum disorder (27%), behavioral problems (18%) 2

Ophthalmologic assessment:

• Visual acuity, fundoscopy for optic atrophy
• Electroretinography if retinal dystrophy suspected (cone-rod dystrophy suggests mitochondrial disorders or SCA7) 6

Audiometry: Sensorineural hearing loss may indicate mitochondrial involvement 6

Recommended Investigations

First-Line Neurophysiology 7:

1. EEG with simultaneous EMG-accelerometry:

• Identify cortical correlate of myoclonus
• Detect giant somatosensory evoked potentials (SEPs)
• Cortical hyperexcitability predicts progression to PME phenotype 2
• Absence of cortical hyperexcitability (non-cortical myoclonus) associates with milder PMA phenotype without epilepsy 2

2. Motor Evoked Potentials (MEPs):

• Measure central motor conduction time (CMCT) to quantify pyramidal tract dysfunction 8
• Prolonged CMCT confirms corticospinal involvement
• CMCT correlates with disease duration in spastic ataxias 8

3. Nerve conduction studies: Exclude peripheral neuropathy 7

Neuroimaging 9:

MRI brain without contrast is the optimal modality:

• Assess for cerebellar and cerebral atrophy
• Evaluate basal ganglia for iron deposition (T2*/SWI sequences)
• Look for "eye-of-the-tiger sign" in globus pallidus (suggests NBIA type 1/pantothenate kinase-associated neurodegeneration) 9
• Diffusion tensor imaging (DTI): Reduced fractional anisotropy in corticospinal tracts quantifies pyramidal involvement 8

Brain FDG-PET (if MRI non-diagnostic):

• May reveal metabolic abnormalities earlier than structural MRI 10
• Bilateral temporal hypermetabolism suggests limbic involvement
• Consider if high clinical suspicion despite negative MRI 10

Genetic Testing Strategy 1, 2:

Priority approach based on your patient's phenotype:

1. First-tier panel (spastic ataxia with myoclonus):

   • GOSR2, SEMA6B (if negative myoclonus present)
   • ARSACS (SACS gene) - most common spastic ataxia
   • SYNE1, ANO10, KIF1C
   • SPTBN2, KCNC3

2. Second-tier (if first panel negative):

   • ATM, NUS1, PRKCG, ITPR1
   • Consider mitochondrial DNA sequencing
   • POLR1A, TPP1, DHDDS

3. Whole exome/genome sequencing if targeted panels negative (identifies etiology in 82% of PMA cases) 2

4. Repeat expansion testing if phenotype evolves:

   • SCA7 (if retinal dystrophy develops)
   • Friedreich's ataxia (FXN) - can present with spasticity 11

Additional Laboratory Tests:

• Celiac antibodies (celiac disease is an acquired, treatable cause of myoclonus-ataxia) 1
• Lactate, pyruvate (mitochondrial screening)
• Muscle biopsy with oxidative enzyme histochemistry if mitochondrial disorder suspected (look for subsarcolemmal mitochondrial aggregates) 6

Management Approach

Symptomatic Treatment:

For myoclonus:

• Levetiracetam (first-line)
• Valproic acid
• Clonazepam
• Piracetam (where available)

For spasticity:

• Baclofen (oral or intrathecal for severe cases)
• Tizanidine
• Physical therapy with structured protocols 6

For ataxia:

• Coordinated physiotherapy
• Occupational therapy for activities of daily living
• Fall prevention strategies (critical given 100% fall rate with negative myoclonus) 5

Monitoring:

• Annual ophthalmologic surveillance 6
• Serial CMCT measurements may track pyramidal tract progression 8
• Gross Motor Function Classification System (GMFCS) scores to quantify disability 5

Critical Pitfalls to Avoid

1. Don't miss treatable causes: Always exclude celiac disease before pursuing extensive genetic testing 1

2. Don't assume pure PMA: The presence of pyramidal signs significantly alters the genetic differential and prognosis - these patients have earlier onset, longer disease duration, and greater motor impairment 3

3. Don't overlook negative myoclonus: This can be missed clinically if preceded by positive myoclonus but predicts worse outcomes 5

4. Don't stop at negative targeted panels: 82% of PMA cases have identifiable genetic causes with comprehensive testing 2

5. Recognize the PMA-PME spectrum: 18% of PMA patients evolve toward PME phenotype; cortical hyperexcitability on neurophysiology predicts this progression 2